MDA-MB-231 was chosen because it represents basal-like, triple-negative breast cancer, which is a subgroup of breast cancer with frequent MYC amplification and/or high MYC pathway activity (2). The gene discussed is MYC; the disease is triple-negative breast carcinoma.